Intravenous Lidocaine and Quality of Recovery After Cesarean Delivery

Sponsor
Northwestern University (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02257346
Collaborator
(none)
0
1
2
3.5
0

Study Details

Study Description

Brief Summary

When given intravenously, the local anesthetic lidocaine has been shown to decrease the amount of pain medication patients require when recovering from several types of surgeries. Cesarean delivery is a very common surgery in the United States, effecting more than 1 million women each year. The investigators hypothesize that lidocaine, given during and immediately after a patient undergoes a cesarean section, will help improve a mother's overall recovery experience, as well as positively influence bonding with her new baby.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Pain after Cesarean delivery is a common occurrence on the labor and delivery unit. The increased use of neuraxial anesthesia has allowed the administration of neuraxial opioids to help with postoperative pain control. Many patients, however, still require IV and oral opioids in the post anesthesia recovery unit (PACU), and on the postpartum nursing floor. Post Cesarean delivery pain not only has the usual adverse effects common to all postoperative pain (i.e. increased risk for deep vein thrombosis, pulmonary embolism, coronary ischemia, pneumonia, poor wound healing, and psychological dysfunction) but also has the potential to adversely affect mother-baby bonding, time spent in skin-to-skin contact and success of initiating effective breastfeeding.

Systemic administration of lidocaine has been shown to decrease opioid consumption, improve recovery of bowel function and promote a better recovery after inpatient procedures. Lidocaine has been shown to have analgesic, antihyperalgesic and anti-inflammatory properties. It also has an excellent safety profile when given by a low-dose infusion.

Assessing a patient's quality of recovery has become an important outcome in several studies. The patient's capacity to return to her normal activities and effectively care for her newborn is one of the most important signs of a successful surgical procedure, and it has significant economic, sociological and psychological implications.

Quality of recovery -40(QoR-40) is a validated 40-item instrument to assess the quality of post-operative recovery (10). Myles et al. have concluded that the QoR-40 would be a useful outcome measure to assess the impact on changes in health care delivery, but anesthesia studies underutilize this instrument.

This study will evaluate the effect of perioperative systemic lidocaine in the postoperative quality of recovery of patients undergoing Cesarean delivery.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
The Effect of Perioperative Systemic Lidocaine on Quality of Recovery After Cesarean Delivery
Actual Study Start Date :
Nov 1, 2014
Actual Primary Completion Date :
Feb 15, 2015
Actual Study Completion Date :
Feb 15, 2015

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Lidocaine

Intravenous lidocaine 1.5 mg/Kg bolus dose and 2mg/Kg/hr infusion

Drug: Lidocaine
Lidocaine infusion will be administered immediately after delivery of the fetus and continue through 1 hour into recovery period.
Other Names:
  • Xylocaine
  • Placebo Comparator: Normal Saline

    Intravenous normal saline infusion

    Drug: Normal Saline
    Normal Saline will be administered as a placebo immediately after delivery of the fetus and continue through 1 hour into recovery period
    Other Names:
  • 0.9% Saline
  • Outcome Measures

    Primary Outcome Measures

    1. Quality of Recovery 40 on the day after surgery [1 day]

      The quality of recovery 40 (QoR-40) is a validated questionnaire used to assess several variables that effect a patient's post-operative experience.

    Secondary Outcome Measures

    1. Opioid consumption [1 day]

      Total opioid consumption for the first 24 hours after delivery

    2. Skin-to-skin time [1 day]

      Percentage of time a patient spends in skin to skin contact with their newborn in the first 24 hours.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • American Society of Anesthesiologists Class II

    • English speaking

    • Scheduled Cesarean delivery

    Exclusion Criteria:
    • Allergy to local anesthetics

    • Chronic opioid use

    • Greater than 2 prior cesarean deliveries

    • Prior myomectomy

    • Prior classical cesarean incision

    • BMI greater than 40

    • History of cardiac disease

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 NorthwesternUniversity Chicago Illinois United States 60611

    Sponsors and Collaborators

    • Northwestern University

    Investigators

    • Principal Investigator: Jason R Farrer, M.D., Northwestern University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Jason Farrer, Clinical Instructor, Northwestern University
    ClinicalTrials.gov Identifier:
    NCT02257346
    Other Study ID Numbers:
    • Lidocaine-RCT
    First Posted:
    Oct 6, 2014
    Last Update Posted:
    Jun 9, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Jason Farrer, Clinical Instructor, Northwestern University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 9, 2022